Rare Bladder Metastasis From Kidney Cancer Emerges After Targeted Therapy Fails

A fifty-year-old woman walked into a hospital for what should have been a routine check-up, carrying no symptoms at all. An ultrasound revealed a mass in her left kidney, and further imaging delivered a devastating verdict: clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer, already invading the adrenal gland on the same side, with suspicious nodules on the opposite adrenal gland pointing to metastatic spread. What followed over the next two years reads like a clinical odyssey through nearly every weapon in modern oncology, and it has now been documented in a rare case report that sheds light on one of the strangest behaviors of this disease: its capacity to appear in places kidney cancer almost never goes, including the bladder.

Renal cell carcinoma ranks as the seventh most common malignant tumor in men and the tenth most common in women worldwide. Roughly one in four to one in three patients already harbor distant metastases when they are first diagnosed, with the disease seeding most frequently into regional lymph nodes, lungs, bones, and liver. Yet the bladder is an extraordinarily uncommon destination. Fewer than seventy cases of bladder metastasis from renal cell carcinoma have ever been reported in the medical literature, and virtually none have described this pattern emerging after a patient had already undergone radical nephrectomy, metastasectomy, and multiple lines of targeted therapy. That is precisely what makes this new case, published in Clinical Case Reports by clinicians at the First Affiliated Hospital of Zhejiang University School of Medicine, so noteworthy.

The technical details of the initial diagnosis illustrate how modern imaging dissects a renal mass. Contrast-enhanced computed tomography showed the tumor lighting up intensely during the arterial phase, a signature of the rich, disordered blood supply that characterizes clear cell carcinoma, while uneven enhancement pointed to localized ischemic necrosis deep within the lesion. These findings ruled out the principal differential diagnoses, including renal tuberculosis, kidney stones, renal cysts, and hamartomas, and staged the disease as T4N0M1, meaning a locally advanced primary tumor with distant metastatic involvement but no lymph node spread. Surgeons proceeded with a laparoscopic radical left nephrectomy, and pathology under the microscope confirmed clear cell renal cell carcinoma.

Because the disease was already metastatic at diagnosis, the oncology team initiated adjuvant systemic therapy with sunitinib, a tyrosine kinase inhibitor delivered at fifty milligrams daily. Sunitinib has historically been a cornerstone of first-line treatment, with landmark trials demonstrating significantly prolonged overall survival compared with interferon alpha. In this patient, however, the drug failed. Within three months, follow-up CT scans showed clear progression of the metastasis in the right adrenal gland. Surgeons removed the gland, pathology again confirming infiltration by clear cell carcinoma, and the team switched to a second tyrosine kinase inhibitor, axitinib at five milligrams twice daily, with imaging every three months. The message was already becoming unmistakable: this tumor was proving refractory to the standard pharmacological arsenal.

Ten months after the original surgery, the patient developed pain in her right thumb. Hand CT imaging revealed osteolytic bone destruction, a hole eaten into the base of the first metacarpal by metastatic cells, with associated soft tissue involvement. Surgeons resected the metastatic bone tumor, reconstructed the defect with a bone graft, and fixed it internally. Pathology confirmed clear cell renal cell carcinoma metastasis. One week later, a whole-body F-18 FDG PET/CT scan was performed, and the results expanded the map of the disease dramatically: the tracer lit up metastatic deposits in the skull, and, remarkably, in the bladder.

Cystoscopy, the direct visual inspection of the bladder interior, revealed two red neoplastic lesions on the bladder wall. Transurethral resection removed the tissue, and histopathological examination confirmed the stunning diagnosis: metastatic clear cell renal cell carcinoma growing inside the bladder, entirely asymptomatic. This last point carries real clinical weight. According to prior literature, roughly seventy percent of patients with bladder metastasis from renal cell carcinoma present with hematuria, visible blood in the urine. This patient had none. Her bladder metastasis was found purely incidentally on PET imaging, a discovery that would likely have been delayed, perhaps indefinitely, in a less thoroughly monitored patient.

Facing relentless progression, the clinicians escalated to combination therapy, pairing axitinib with toripalimab, an immune checkpoint inhibitor, at 240 milligrams. The rationale rested on recent phase III evidence from the RENOTORCH trial, which demonstrated that the combination of toripalimab and axitinib delivered superior clinical benefit compared with sunitinib monotherapy as first-line treatment for advanced renal cell carcinoma. The combination appeared to achieve local control where it mattered most in this case: after transurethral resection of the bladder tumor, follow-up cystoscopic examinations showed no evidence of bladder tumor recurrence, even after a full year of continuous combination therapy. Yet the systemic disease refused to stand still. Three months before the report was finalized, routine abdominal CT revealed new metastatic lesions in the right ninth rib and in the bilateral iliac bones of the pelvis, signaling that distant skeletal spread was continuing despite the intensified regimen.

The trajectory of this case underscores a sobering paradox in contemporary kidney cancer treatment. Targeted therapy and immunotherapy have genuinely transformed outcomes in advanced renal cell carcinoma, extending survival in large prospective clinical trials and converting what was once an almost uniformly fatal diagnosis into a chronic disease for many patients. Prolonged survival, however, creates a longer window in which the biology of the tumor can express itself in unusual ways, and clinicians are increasingly reporting metastases to rare sites such as the esophagus, the eyeball, and now the bladder. Previous case reports of bladder metastasis typically described patients with localized renal tumors who developed isolated bladder recurrence several years after partial or radical nephrectomy, without disease elsewhere, or involved non-classical histological subtypes. No previous report, as far as the authors know, had documented bladder metastasis in advanced renal cell carcinoma developing after first-line targeted therapy in a patient with widespread systemic disease.

Over the course of her care, this patient underwent five salvage tumor resections, including the nephrectomy, adrenalectomy, metacarpal resection, cranial metastasis resection, and transurethral bladder tumor resection, alongside continuously evolving systemic therapy. The authors emphasize that resecting bladder metastases may reduce local recurrence but cannot suppress distant spread, and that there is currently no standardized clinical guideline for managing bladder metastasis of renal cell carcinoma at all. For patients like this one, who remain refractory to first-line and second-line regimens and continue to accumulate metastases, the authors argue that genomic profiling to identify novel therapeutic targets may offer the next realistic avenue of clinical benefit. The patient remains under active follow-up, generally stable in condition even as her bone metastases progress, and her treatment regimen is expected to require further adjustment.

The broader lesson for clinicians and researchers alike is vigilance. Bladder metastasis of renal cell carcinoma is rare enough to escape suspicion, and its frequent association with hematuria means an asymptomatic presentation, as in this case, could easily evade detection without systematic PET/CT surveillance and cystoscopic confirmation. As targeted agents and immune checkpoint inhibitors continue to extend the lives of patients with metastatic kidney cancer, the population of long-term survivors will grow, and with it the likelihood that oncologists will encounter metastatic patterns that current guidelines never anticipated. This single patient’s two-year journey, from an incidental ultrasound finding to a bladder seeded with kidney cancer that never once bled, is a vivid reminder that in advanced clear cell renal cell carcinoma, the map of metastasis is still being drawn, and every unusual case redraws it a little further.

Subject of Research: A rare case of asymptomatic bladder metastasis from advanced clear cell renal cell carcinoma following radical nephrectomy, metastasectomy, and targeted and immunotherapy.

Article Title: Metastatic Clear Renal Cell Carcinoma in Bladder Following Radical Nephrectomy, Metastasectomy, and Targeted Therapy: A Rare Case Report

Article References: Zheng, X., Jiang, P., & Zhou, J. (2026). Metastatic Clear Renal Cell Carcinoma in Bladder Following Radical Nephrectomy, Metastasectomy, and Targeted Therapy: A Rare Case Report. Clinical Case Reports, 14(9), Article e73557. https://doi.org/10.1002/ccr3.73557

Image Credits: AI Generated

DOI: 10.1002/ccr3.73557

Keywords: clear cell renal cell carcinoma, bladder metastasis, radical nephrectomy, sunitinib, axitinib, toripalimab, tyrosine kinase inhibitor, immunotherapy, bone metastasis, FDG PET/CT, cystoscopy, case report